RxDoctor Payments Data

Bruce Burton, MD

Internal Medicine · Malvern, ARNPI 1952497240

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 37 payments — averaging $30.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$356
  • GSK$264
  • Novartis$157
  • Boston Scientific$113
  • Johnson & Johnson$70
  • Exact Sciences$37
  • plus $125 from 8 others

What the payments were for

  • Food & beverage$1,11699%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,122 in reported general payments places this provider in the 75th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$55,595
Medicare patients
197
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban579$178,402
XareltoRivaroxaban94$25,856
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,897
JardianceEmpagliflozin61$18,445
FarxigaDapagliflozin Propanediol33$15,387
EntrestoSacubitril/Valsartan18$9,172
JanuviaSitagliptin Phosphate27$7,704
Breo ElliptaFluticasone/Vilanterol16$6,951
FiaspInsulin Aspart (Niacinamide)22$6,886
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$6,340
LinzessLinaclotide11$6,196
Sucralfate98$6,021
Potassium Chloride340$5,955
Atorvastatin Calcium355$5,874
LantusInsulin Glargine,hum.Rec.Anlog61$5,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$178,402579 claims
GSKTrelegy Ellipta, Breo Ellipta$264$26,84845 claims
Johnson & JohnsonXarelto$70$25,85694 claims
AstraZenecaFarxiga$356$15,38733 claims
NovartisEntresto$157$9,17218 claims
MerckJanuvia$18$7,70427 claims
AbbVieLinzess$11$6,19611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Malvern

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →